We are live on ! Find out more
PAI

Palo Alto Investors Portfolio holdings

AUM $654M
1-Year Est. Return 77.8%
This Fund
S&P 500
This Quarter Est. Return
+44.94%
1 Year Est. Return
+77.8%
3 Year Est. Return
+127.05%
5 Year Est. Return
+199.24%
10 Year Est. Return
+2,229.57%
AUM
$1.82B
AUM Growth
+$315M
Cap. Flow
-$132M
Cap. Flow %
-7.25%
Top 10 Hldgs %
68.81%
Holding
39
New
2
Increased
2
Reduced
21
Closed
2

Top Buys

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$2.44M
2
FOLD
Amicus Therapeutics
FOLD
+$2.3M
3
RVNC
Revance Therapeutics, Inc.
RVNC
+$1.37M
4
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$449K

Top Sells

Rank Stock Value
1
ALDR
Alder Biopharmaceuticals
ALDR
+$35.1M
2
ABMD
Abiomed Inc
ABMD
+$16.7M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$14.2M
4
UTHR icon
United Therapeutics
UTHR
+$11.9M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$11.8M

Sector Composition

Rank Sector Weight
1 Healthcare 84.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMRN icon
1
BioMarin Pharmaceuticals
BMRN
$13.3B
$171M 9.41%
2,021,136
-188,368
-9% -$14.2M
INSM icon
2
Insmed
INSM
$28.9B
$164M 9%
6,848,760
-390,889
-5% -$7.95M
EPZM
3
DELISTED
Epizyme, Inc
EPZM
$151M 8.32%
6,145,945
-208,714
-3% -$3.1M
STAA icon
4
STAAR Surgical
STAA
$1.26B
$133M 7.32%
3,778,938
-111,755
-3% -$3.69M
IMMU
5
DELISTED
Immunomedics Inc
IMMU
$125M 6.9%
5,923,195
-261,125
-4% -$4.61M
UTHR icon
6
United Therapeutics
UTHR
$22.6B
$114M 6.25%
1,288,902
-135,499
-10% -$11.9M
AIMT
7
DELISTED
Aimmune Therapeutics
AIMT
$113M 6.23%
3,380,441
-91,299
-3% -$2.55M
ABMD
8
DELISTED
Abiomed Inc
ABMD
$96.2M 5.3%
564,168
-90,260
-14% -$16.7M
ALXN
9
DELISTED
Alexion Pharmaceuticals
ALXN
$95M 5.23%
878,100
-79,850
-8% -$8.54M
KPTI icon
10
Karyopharm Therapeutics
KPTI
$44.6M
$88.1M 4.85%
306,333
-16,477
-5% -$3.57M
ACAD icon
11
Acadia Pharmaceuticals
ACAD
$5.04B
$81.5M 4.49%
1,905,374
-271,303
-12% -$11.8M
WMGI
12
DELISTED
Wright Medical Group Inc
WMGI
$75.1M 4.13%
2,463,055
-31,200
-1% -$817K
VNDA icon
13
Vanda Pharmaceuticals
VNDA
$296M
$74.3M 4.09%
4,525,476
-55,700
-1% -$842K
FOLD
14
DELISTED
Amicus Therapeutics
FOLD
$72.2M 3.98%
7,413,920
+251,000
+4% +$2.3M
CLVS
15
DELISTED
Clovis Oncology, Inc.
CLVS
$52.7M 2.9%
5,056,286
+335,542
+7% +$2.44M
SAGE
16
DELISTED
Sage Therapeutics
SAGE
$47.2M 2.6%
653,594
-27,300
-4% -$3.36M
AMAG
17
DELISTED
AMAG Pharmaceuticals
AMAG
$37M 2.04%
3,044,374
-34,500
-1% -$377K
ALGN icon
18
Align Technology
ALGN
$12.5B
$35.6M 1.96%
127,505
-20,000
-14% -$4.99M
MNTA
19
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$33.3M 1.83%
1,685,372
-71,750
-4% -$1.15M
PRTA icon
20
Prothena Corp
PRTA
$451M
$15.7M 0.87%
992,749
-11,700
-1% -$125K
PBYI icon
21
Puma Biotechnology
PBYI
$448M
$11.8M 0.65%
1,349,180
-56,500
-4% -$468K
RIGL icon
22
Rigel Pharmaceuticals
RIGL
$765M
$7.58M 0.42%
354,255
-4,480
-1% -$92.2K
DRNA
23
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$7.31M 0.4%
331,813
– –
KLDO
24
DELISTED
Kaleido Biosciences, Inc. Common Stock
KLDO
$3.96M 0.22%
787,999
– –
GILD icon
25
Gilead Sciences
GILD
$165B
$2.55M 0.14%
39,300
– –
1
2

Similar funds

RRA
Round Rock Advisors Wilton, Connecticut $654M AUM 22.95% 1-Year Est. Return
AG
Alibaba Group Causeway Bay, Hong Kong $653M AUM 16.11% 1-Year Est. Return
BL
BWCP LP Dallas, Texas $656M AUM 41.58% 1-Year Est. Return
CG
CFO4Life Group Coppell, Texas $656M AUM 17.88% 1-Year Est. Return
SCM
Stevens Capital Management Radnor, Pennsylvania $649M AUM 27.37% 1-Year Est. Return
GAMA
Graticule Asia Macro Advisors New York $649M AUM
PIM
Parker Investment Management Menlo Park, California $659M AUM 52.52% 1-Year Est. Return
ACA
Apis Capital Advisors New York $648M AUM 302.67% 1-Year Est. Return

Palo Alto Investors's Q4 2019 Portfolio in Review

As of Q4 2019, Palo Alto Investors held 39 positions worth $1.82B, up 21% from $1.5B the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Palo Alto Investors withdrew a net $132M in Q4 2019, closing 2 positions and reducing 21 holdings. Its most notable exit was Alder Biopharmaceuticals, an estimated $35.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, down from 87% a quarter earlier.

Against the trend, Palo Alto Investors opened a new position in Revance Therapeutics, Inc. worth $1.44M.

  • Palo Alto Investors's largest Q4 2019 buy was Revance Therapeutics, Inc.: 88,590 shares worth $1.44M.
  • Palo Alto Investors added most to Clovis Oncology, Inc. in Q4 2019, an estimated $2.44M increase.
  • Palo Alto Investors's biggest Q4 2019 reduction was Abiomed Inc, cutting an estimated $16.7M.
  • Palo Alto Investors fully exited Alder Biopharmaceuticals in Q4 2019, selling an estimated $35.1M.
  • Palo Alto Investors's ten largest holdings make up 69% of its $1.82B portfolio in Q4 2019.
  • Palo Alto Investors opened 2 new positions and closed 2 in Q4 2019.
  • Palo Alto Investors's portfolio value rose 21% quarter-over-quarter to $1.82B.

Based on Palo Alto Investors's 13F filing for Q4 2019, filed 14 Feb 2020.